Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Director | November 11, 2022 | November 16, 2022 |
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Director | June 06, 2023 | June 08, 2023 |
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Director | May 25, 2023 | May 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mirum Pharmaceuticals, Inc.
Report date November 11, 2022 · Filed November 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy RiverVest Venture Fund IV, L.P. | 1,621,118 |
Last balance in matching sequence
After 2022-11-15 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2022-11-11 · Sale · Disposed 174,121 · Balance 1,746,997 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.28, inclusive. The reporting persons undertake to provide Mirum Pharmaceuticals, Inc., any security holder of Mirum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4. F2: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Row 2 · 2022-11-14 · Sale · Disposed 32,109 · Balance 1,714,888 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.105 to $20.43, inclusive. F2: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Row 3 · 2022-11-15 · Sale · Disposed 93,770 · Balance 1,621,118 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $20.32, inclusive. F2: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.28, inclusive. The reporting persons undertake to provide Mirum Pharmaceuticals, Inc., any security holder of Mirum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4.
F2: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.105 to $20.43, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $20.32, inclusive.
OnKure Therapeutics, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.01 · Expires 2033-06-05 | Direct | 17,500 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 17,500 · Balance 17,500 F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
SPRUCE BIOSCIENCES, INC.
Report date May 25, 2023 · Filed May 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.26 · Expires 2033-05-24 | Direct | 30,000 |
Reported balance
After 2023-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-25 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2024 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2024 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2023 Filed Jun 8, 2023 22:13 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $9.01 | $0.00 |
DisclosureSEC source: 0001209191-23-035562 · doc4.xml · derivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2033-06-05 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| May 25, 2023 Filed May 26, 2023 21:39 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001209191-23-032659 · doc4.xml · derivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2024 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| May 08, 2023 Filed May 10, 2023 21:47 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 125,000 | $8.00 | $1,000,000.00 |
DisclosureSEC source: 0001209191-23-028533 · doc4.xml · nonDerivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 2,188,713 F1 · kind: The shares were purchased in the Issuer's public offering. F2 · ownership.nature: The shares held by RiverVest Venture Fund IV, L.P. ("RiverVest Fund IV") are indirectly held by RiverVest Venture Partners IV, L.P., its general partner ("RiverVest Partners IV"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV. Read SEC document |
| February 16, 2023 Filed May 16, 2023 20:08 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | PurchaseCommon Stock Warrant (Right to Buy) · Derivative | 472,800 | Not disclosed Strike: $3.96 | Not disclosed |
DisclosureSEC source: 0001209191-23-029764 · doc4.xml · derivative · entry 2 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 472,800 Underlying: Common Stock · 472,800 shares Expires 2028-02-16 F4 · kind: The warrant was purchased in the Issuer's private offering. F2 · price: Represents the combined purchase price of $3.17 for Common Stock and Warrants acquired from Issuer in a private offering. F3 · ownership.nature: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Read SEC document |
| February 16, 2023 Filed May 16, 2023 20:08 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | PurchaseCommon Stock | 630,400 | $3.17 | $1,998,368.00 |
DisclosureSEC source: 0001209191-23-029764 · doc4.xml · nonDerivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 1,326,305 F1 · kind: The shares were purchased in the Issuer's private offering. F2 · price: Represents the combined purchase price of $3.17 for Common Stock and Warrants acquired from Issuer in a private offering. F3 · ownership.nature: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 01:02 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 93,770 | $19.69 | $1,846,021.86 |
DisclosureSEC source: 0000899243-22-035944 · doc4.xml · nonDerivative · entry 3 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 1,621,118 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $20.32, inclusive. F2 · ownership.nature: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 01:02 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 32,109 | $19.60 | $629,423.09 |
DisclosureSEC source: 0000899243-22-035944 · doc4.xml · nonDerivative · entry 2 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 1,714,888 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.105 to $20.43, inclusive. F2 · ownership.nature: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Read SEC document |
| November 11, 2022 Filed Nov 16, 2022 01:02 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 174,121 | $19.99 | $3,481,410.10 |
DisclosureSEC source: 0000899243-22-035944 · doc4.xml · nonDerivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 1,746,997 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.28, inclusive. The reporting persons undertake to provide Mirum Pharmaceuticals, Inc., any security holder of Mirum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4. F2 · ownership.nature: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:55 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $23.51 | $0.00 |
DisclosureSEC source: 0001209191-22-034628 · doc4.xml · derivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2023 annual stockholder meeting. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:00 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-22-034175 · doc4.xml · derivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 1, 2023 or the day prior to the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:16 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001209191-22-032519 · doc4.xml · derivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2023 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $16.88 | $0.00 |
DisclosureSEC source: 0001209191-21-038932 · doc4.xml · derivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2022 annual stockholder meeting. Read SEC document |
| May 20, 2021 Filed May 22, 2021 01:09 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $15.24 | $0.00 |
DisclosureSEC source: 0001209191-21-035150 · doc4.xml · derivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2022 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:16 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | ConversionSeries B Preferred Stock · Derivative | 3,710,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026826 · doc4.xml · derivative · entry 5 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 829,113 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares held by RiverVest Venture Fund IV, L.P. ("RiverVest Fund IV") are indirectly held by RiverVest Venture Partners IV, L.P., its general partner ("RiverVest Partners IV"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:16 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | ConversionSeries A Preferred Stock · Derivative | 4,629,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026826 · doc4.xml · derivative · entry 4 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,034,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares held by RiverVest Venture Fund IV, L.P. ("RiverVest Fund IV") are indirectly held by RiverVest Venture Partners IV, L.P., its general partner ("RiverVest Partners IV"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:16 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 200,000 | $15.00 | $3,000,000.00 |
DisclosureSEC source: 0001209191-21-026826 · doc4.xml · nonDerivative · entry 3 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 2,063,713 F3 · kind: The shares were purchased in the Issuer's initial public offering. F2 · ownership.nature: The shares held by RiverVest Venture Fund IV, L.P. ("RiverVest Fund IV") are indirectly held by RiverVest Venture Partners IV, L.P., its general partner ("RiverVest Partners IV"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:16 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | ConversionCommon Stock | 829,113 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-026826 · doc4.xml · nonDerivative · entry 2 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 1,863,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares held by RiverVest Venture Fund IV, L.P. ("RiverVest Fund IV") are indirectly held by RiverVest Venture Partners IV, L.P., its general partner ("RiverVest Partners IV"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:16 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | ConversionCommon Stock | 1,034,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-026826 · doc4.xml · nonDerivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 1,034,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares held by RiverVest Venture Fund IV, L.P. ("RiverVest Fund IV") are indirectly held by RiverVest Venture Partners IV, L.P., its general partner ("RiverVest Partners IV"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 19:18 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026340 · doc4.xml · derivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-04-07 F1 · derivative.exercise_date: The shares subject to the option vest on April 8, 2022. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 16:21 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | ConversionSeries B Preferred Stock · Derivative | 2,916,664 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055015 · doc4.xml · derivative · entry 3 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 445,905 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date. F1 · derivative.underlying_shares: Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date. F2 · ownership.nature: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 16:21 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | PurchaseCommon Stock | 250,000 | $15.00 | $3,750,000.00 |
DisclosureSEC source: 0001209191-20-055015 · doc4.xml · nonDerivative · entry 2 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 695,905 F3 · kind: The shares were purchased in the Issuer's initial public offering. F3 · shares: The shares were purchased in the Issuer's initial public offering. F2 · ownership.nature: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 16:21 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | ConversionCommon Stock | 445,905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055015 · doc4.xml · nonDerivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 445,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date. F2 · ownership.nature: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:20 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $16.71 | $0.00 |
DisclosureSEC source: 0001209191-20-036597 · doc4.xml · derivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2021 annual stockholder meeting. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 20:16 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | ConversionSeries A Preferred Stock · Derivative | 11,968,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043023 · doc4.xml · derivative · entry 3 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,496,118 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date. F1 · derivative.underlying_shares: Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date. F2 · ownership.nature: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 20:16 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 300,000 | $15.00 | $4,500,000.00 |
DisclosureSEC source: 0001209191-19-043023 · doc4.xml · nonDerivative · entry 2 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 1,921,118 F3 · kind: The shares were purchased in the Issuer's initial public offering. F2 · ownership.nature: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 20:16 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | ConversionCommon Stock | 1,496,118 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043023 · doc4.xml · nonDerivative · entry 1 O'Donnell Niall · CIK 0001780235 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By RiverVest Venture Fund IV, L.P. Disclosed balance after: 1,621,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date. F2 · ownership.nature: RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.